Koers Kanabo Group Plc London S.E.
Aandelen
SOP
GB00BYQCS703
Farmaceutische producten
Omzet 2021 | 73K 91,19K 85,26K | Omzet 2022 | 603K 753K 704K | Marktkapitalisatie | 8,04 mln. 10,04 mln. 9,38 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -4 mln. -5 mln. -4,67 mln. | Nettowinst (verlies) 2022 | -6 mln. -7,5 mln. -7,01 mln. | EV/omzet 2021 | 648 x |
Nettoliquiditeiten 2021 | 4,5 mln. 5,62 mln. 5,25 mln. | Nettoliquiditeiten 2022 | 3,01 mln. 3,76 mln. 3,52 mln. | EV/omzet 2022 | 8,33 x |
K/w-verhouding 2021 |
-9,98
x | K/w-verhouding 2022 |
-1,15
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 50,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Avihu Tamir
CEO | Chief Executive Officer | - | - |
Assaf Vardimon
DFI | Director of Finance/CFO | 46 | - |
Ophir Shimshi
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ian Mattioli
CHM | Chairman | 62 | 09-05-23 |
David Tsur
BRD | Director/Board Member | 73 | 28-06-21 |
Sharon Malka
BRD | Director/Board Member | 51 | 04-05-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |